Pair page
Matrixyl with Vialox
Mechanism-tag overlap and published literature for Matrixyl and Vialox, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
collagen-signal-peptidecosmetic-peptide
cosmetic-neuromuscular-inhibitor
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Matrixyl and Vialox have published these mechanism-level observations. Not a co-administration recommendation.
A signal peptide that promotes collagen and extracellular-matrix synthesis in fibroblast cultures. Mechanism is entirely distinct from Vialox (signal peptide addressing static-aging changes vs neuromuscular peptide addressing dynamic-aging changes). Combination addresses two different aging axes — dynamic wrinkles plus dermal-matrix loss.
Quick facts
Matrixyl
Vialox
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2009 | Matrixyl | Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. PMID: 19570099. (UCSF Dermatology systematic review of topical peptides for aged skin, including Pal-KTTKS signal-peptide class.) PMID 19570099 | systematic review |
| 2010 | Matrixyl | Fu JJ, Hillebrand GG, Raleigh P, Li J, Marmor MJ, Bertucci V, Grimes PE, Mandy SH, Perez MI, Weinkle SH, Kaczvinsky JR. A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescri… PMID 20374604 | human trial |
| 2024 | Matrixyl | Vitali A, Paolicelli P, Bigi B, Trilli J, Di Muzio L, Carriero VC, Casadei MA, Petralito S. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization. Pharmaceutics. 2024;16(2):219. PMID: 38399273. (Liposomal delivery system for Pal-KTTKS… PMID 38399273 | preclinical, in vitro |
| 2017 | Matrixyl | Park H, An E, Cho Lee AR. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression. Tissue Eng Regen Med. 2017;14(1):73-80. PMID: 30603464. (CTGF / α-SMA modulation and fibrobl… PMID 30603464 | preclinical, in vitro |
| 2014 | Matrixyl | Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014;22(4):321-327. PMID: 25143811. (Demonstrates palmitoylation as stability and permeation enhancer relative to un… PMID 25143811 | preclinical, in vitro |
| 2013 | Matrixyl | Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Mol Pharm. 2013;10(3):1063-1069. PMID: 23320752. (Direct fibroblast collagen-production dose-response for Pal-KTTKS linked to critical-aggregation-con… PMID 23320752 | preclinical, in vitro |
| 2019 | Matrixyl | Tałałaj U, Uscinowicz P, Bruzgo I, Surazynski A, Zareba I, Markowska A. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. Molecules. 2019;24(20):3698. PMID: 31618846. (Structure-activity series of KTTKS analogues with acetyl / lipoyl / pa… PMID 31618846 | mechanism / discovery |
| 2019 | Matrixyl | Mortazavi SM, Kobarfard F, Maibach HI, Moghimi HR. Effect of Palmitic Acid Conjugation on Physicochemical Properties of Peptide KTTKS: A Preformulation Study. J Cosmet Sci. 2019;70(6):299-312. PMID: 31829923. (Physicochemical characterization of palmitoyl conjugation effects on… PMID 31829923 | mechanism / discovery |
| 2007 | Matrixyl | Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. PMID: 18045359. (Updated Dermatologic Therapy review of signal, neurotransmitter-affecting, and carrier peptides.) PMID 18045359 | review |
| 2005 | Matrixyl | Osborne R, Mullins L, Jarrold B, Lintner K. In vitro skin structure benefits with a new antiaging peptide, Pal-KT. J Am Acad Dermatol. 2005;52(3 Suppl):P34. (AAD-meeting abstract on Pal-KT / Pal-KTTKS cosmetic evaluation; Procter & Gamble / Sederma collaboration.) | industry documentation |
| 2009 | Matrixyl | Trookman NS, Rizer RL, Ford R, Ho E, Gotz V. Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles. J Clin Aesthet Dermatol. 2009;2(3):38-43. PMID: 20729942. (8-week topical treatment clinical study including palmitoyl pentapeptide active… PMID 20729942 | research article |
| 2005 | Matrixyl | Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PMID: 18492182. (The 93-subject 12-week split-face vehicle-controlled RCT of 3 ppm Pa… PMID 18492182 | research article |
| 2025 | Vialox | Mlosek RK, Migda B, Skrzypek E, Słoboda K, Migda M. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025. PMID: 40565185. (2025 systematic review of permeability and efficacy for the closest mechanistic neighbor to Vialox.) PMID 40565185 | systematic review |
| 2013 | Vialox | Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-153. doi:10.1007/s40257-013-0009-9. PMID: 23417317. (Randomized placebo-c… PMID 23417317 | human trial |
| 1995 | Vialox | Tsai MC, Hsieh WH, Smith LA, Lee CY. Effects of waglerin-I on neuromuscular transmission of mouse nerve-muscle preparations. Toxicon. 1995;33(3):363-371. doi:10.1016/0041-0101(94)00158-5. PMID: 7638875. (Functional characterization of waglerin-I at the muscle-type nAChR — direct… PMID 7638875 | preclinical, in vivo |
| 1992 | Vialox | Aiken SP, Sellin LC, Schmidt JJ, Weinstein SA, McArdle JJ. A novel peptide toxin from Trimeresurus wagleri acts pre- and post-synaptically to block transmission at the rat neuromuscular junction. Pharmacol Toxicol. 1992;70(5 Pt 1):339-343. PMID: 1359525. (Mechanism characterizat… PMID 1359525 | preclinical, in vivo |
| 2017 | Vialox | Tan CH, Tan KY, Yap MK, Tan NH. Venomics of Tropidolaemus wagleri, the sexually dimorphic temple pit viper: Unveiling a deeply conserved atypical toxin arsenal. Sci Rep. 2017;7:43237. doi:10.1038/srep43237. (Modern venomics characterization of the temple pit viper venom containi… | mechanism / discovery |
| 1992 | Vialox | Schmidt JJ, Weinstein SA, Smith LA. Molecular properties and structure-function relationships of lethal peptides from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1992;30(9):1027-1036. doi:10.1016/0041-0101(92)90048-a. PMID: 1440639. (Structure-function characteri… PMID 1440639 | mechanism / discovery |
| 1991 | Vialox | Weinstein SA, Schmidt JJ, Bernheimer AW, Smith LA. Characterization and amino acid sequences of two lethal peptides isolated from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1991;29(2):227-236. doi:10.1016/0041-0101(91)90107-3. (Original characterization of the w… | mechanism / discovery |
| 2017 | Vialox | Pai VV, Bhandari P, Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9-18. doi:10.4103/0378-6323.186500. PMID: 27451932. (2017 review of cosmetic peptides including discussion of neurotransmitter inhibitors and curare-mimetic peptides.) PMID 27451932 | review |
| 2017 | Vialox | Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016. (MDPI Cosmetics review of the cosmetic-peptide landscape including Pentapeptide-3 / Vialox; not PubMed-indexed but widely cited.) | review |
| 2018 | Vialox | DSM Personal Care / Pentapharm. Pentapeptide-3 (Vialox PT) — Product Brochure. Basel, Switzerland: DSM; 2018 (and subsequent revisions). (Manufacturer brochure documenting Pentapharm in-house clinical evaluation methodology; the underlying source of the "49% wrinkle reduction" h… | industry documentation |
| 2017 | Vialox | Centerchem Inc. Vialox® Pentapeptide-3 — Technical Data Sheet. Norwalk, CT: Centerchem; 2017 (and subsequent technical bulletins). (Primary manufacturer technical literature describing in-vitro and in-vivo claims; cited here as the documented source of widely repeated wrinkle-re… | industry documentation |
| 2015 | Vialox | Hoppel M, Reznicek G, Kählig H, Kotisch H, Resch GP, Valenta C. Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. Eur J Pharm Sci. 2015;68:27-35. doi:10.1016/j.ejps.2014.11.014. PMID: 25497319. (The most… PMID 25497319 | research article |
Related pair pages
More research context
Frequently asked
Have Matrixyl and Vialox been studied together?
Researchers have published mechanistic-level co-administration discussion of Matrixyl and Vialox. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Matrixyl and Vialox share?
Matrixyl and Vialox do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Matrixyl and Vialox?
Matrixyl: Cosmetic ingredient (not a drug). Vialox: Cosmetic ingredient (not a drug). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Matrixyl and Vialox?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Matrixyl profile and the Vialox profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026